Site has a capital investment program of ~$30 million spent or committed over the last three years to expand capabilities and improve operational efficiencies
During the research term, Olema will contribute funding to Aurigene to facilitate ongoing discovery efforts.
RH Capital, a leading women's health venture capital fund, announced three new investments to improve health outcomes for women in the US.
The partnership between Lockwood and Random42 expands the capabilities and geographic footprint for both organizations.
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
It is part of the company's CAD $30 million capital investment in the Aurora, Canada site
Revolutionary ovarian cancer rapid test available Q4 2022
The plant is expected to start commercial operations from Q4FY24
Under the terms of the agreement, Bachem will provide the appropriate engineering infrastructure and expertise to implement Lilly’s novel oligonucleotide manufacturing technology
A separate global Phase 3 study of S-217622 is underway aiming to recruit participants globally to support regulatory filings this year
Subscribe To Our Newsletter & Stay Updated
